UNLABELLED: Chemokine interactions with their receptors have been implicated in hepatic stellate cell (HSC) activation. The hepatic expression of CXCR4 messenger RNA is increased in hepatitis C cirrhotic livers and plasma levels of its endogenous ligand, stromal cell-derived factor-1alpha (SDF-1alpha), correlate with increased fibrosis in these patients. The expression of CXCR4 by HSCs has not been reported. We therefore examined whether HSCs express CXCR4 in vivo and in vitro and explored whether SDF-1alpha/CXCR4 receptor engagement promotes HSC activation, fibrogenesis, and proliferation. The hepatic protein expression of both CXCR4 and SDF-1alpha is increased in hepatitis C cirrhotic livers and immunoflourescent and immunohistochemical staining confirms that HSCs express CXCR4 in vivo. Immortalized human stellate cells as well as primary human HSCs express CXCR4, and cell surface receptor expression increases with progressive culture-induced activation. Treatment of stellate cells with recombinant SDF-1alpha increases expression of alpha-smooth muscle actin and collagen I and stimulates a dose-dependent increase in HSC proliferation. Inhibitor studies suggest that SDF-1alpha/CXCR4-dependent extracellular signal-regulated kinase 1/2 and Akt phosphorylation mediate effects on collagen I expression and stellate cell proliferation. CONCLUSION: HSCs express CXCR4 receptor in vivo and in vitro. CXCR4 receptor activation by SDF-1alpha is profibrogenic through its effects on HSC activation, fibrogenesis, and proliferation. Extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase pathways mediate SDF-1alpha-induced effects on HSC expression of collagen I and proliferation. The availability of small molecule inhibitors of CXCR4 make this receptor an appealing target for antifibrotic approaches.
UNLABELLED: Chemokine interactions with their receptors have been implicated in hepatic stellate cell (HSC) activation. The hepatic expression of CXCR4 messenger RNA is increased in hepatitis C cirrhotic livers and plasma levels of its endogenous ligand, stromal cell-derived factor-1alpha (SDF-1alpha), correlate with increased fibrosis in these patients. The expression of CXCR4 by HSCs has not been reported. We therefore examined whether HSCs express CXCR4 in vivo and in vitro and explored whether SDF-1alpha/CXCR4 receptor engagement promotes HSC activation, fibrogenesis, and proliferation. The hepatic protein expression of both CXCR4 and SDF-1alpha is increased in hepatitis C cirrhotic livers and immunoflourescent and immunohistochemical staining confirms that HSCs express CXCR4 in vivo. Immortalized human stellate cells as well as primary human HSCs express CXCR4, and cell surface receptor expression increases with progressive culture-induced activation. Treatment of stellate cells with recombinant SDF-1alpha increases expression of alpha-smooth muscle actin and collagen I and stimulates a dose-dependent increase in HSC proliferation. Inhibitor studies suggest that SDF-1alpha/CXCR4-dependent extracellular signal-regulated kinase 1/2 and Akt phosphorylation mediate effects on collagen I expression and stellate cell proliferation. CONCLUSION: HSCs express CXCR4 receptor in vivo and in vitro. CXCR4 receptor activation by SDF-1alpha is profibrogenic through its effects on HSC activation, fibrogenesis, and proliferation. Extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase pathways mediate SDF-1alpha-induced effects on HSC expression of collagen I and proliferation. The availability of small molecule inhibitors of CXCR4 make this receptor an appealing target for antifibrotic approaches.
Authors: Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Valérie Paradis; Dominique Vidaud; Claude Degott; Michelle Martinot; Pierre Bedossa; Dominique Valla; Michel Vidaud; Patrick Marcellin Journal: Gastroenterology Date: 2005-12 Impact factor: 22.682
Authors: Norbert Bräu; Mirella Salvatore; Carlos F Ríos-Bedoya; Alberto Fernández-Carbia; Fiorenzo Paronetto; José F Rodríguez-Orengo; Maribel Rodríguez-Torres Journal: J Hepatol Date: 2005-07-27 Impact factor: 25.083
Authors: F Marra; M C Arrighi; M Fazi; A Caligiuri; M Pinzani; R G Romanelli; E Efsen; G Laffi; P Gentilini Journal: Hepatology Date: 1999-10 Impact factor: 17.425
Authors: Meena B Bansal; Kellen Kovalovich; Ritu Gupta; Wei Li; Akansha Agarwal; Brian Radbill; Carlos E Alvarez; Rifaat Safadi; M Isabel Fiel; Scott L Friedman; Rebecca A Taub Journal: J Hepatol Date: 2005-04 Impact factor: 25.083
Authors: Samuele De Minicis; Ekihiro Seki; Hiroshi Uchinami; Johannes Kluwe; Yonghui Zhang; David A Brenner; Robert F Schwabe Journal: Gastroenterology Date: 2007-02-21 Impact factor: 22.682
Authors: Frederic Sierro; Christine Biben; Laura Martínez-Muñoz; Mario Mellado; Richard M Ransohoff; Meizhang Li; Blanche Woehl; Helen Leung; Joanna Groom; Marcel Batten; Richard P Harvey; Carlos Martínez-A; Charles R Mackay; Fabienne Mackay Journal: Proc Natl Acad Sci U S A Date: 2007-09-05 Impact factor: 11.205
Authors: Jinhua Xiang; James H McLinden; Qing Chang; Thomas M Kaufman; Jack T Stapleton Journal: Proc Natl Acad Sci U S A Date: 2006-10-09 Impact factor: 11.205
Authors: Thomas J LaRocca; Martina Schwarzkopf; Perry Altman; Shihong Zhang; Achla Gupta; Ivone Gomes; Zikiar Alvin; Hunter C Champion; Georges Haddad; Roger J Hajjar; Lakshmi A Devi; Alison D Schecter; Sima T Tarzami Journal: J Cardiovasc Pharmacol Date: 2010-11 Impact factor: 3.105
Authors: Gregory C Wilson; Christopher M Freeman; Joshua W Kuethe; Ralph C Quillin; Hiroyuki Nojima; Rebecca Schuster; John Blanchard; Michael J Edwards; Charles C Caldwell; Alex B Lentsch Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-02-26 Impact factor: 4.052
Authors: Paolo Maggi; Giuseppe Bruno; Francesco Perilli; Annalisa Saracino; Anna Volpe; Carmen Santoro; Nicoletta Ladisa; Gioacchino Angarano Journal: In Vivo Date: 2017-01-02 Impact factor: 2.155